子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | BENZOQUINONE DERIVATIVES FOR TREATING OXIDATIVE STRESS DISORDERS | US14426135 | 2013-09-06 | US20150218079A1 | 2015-08-06 | William D. Shrader; Andrew W. Hinman; Viktoria Kheifets |
| Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging, or for modulating one or more energy biomarkers, normalizing one or more energy biomarkers, or enhancing one or more energy biomarkers, wherein the compound is a compound of Formula I or Formula II: wherein: R1 and R2 are independently hydrogen, (C1-C6)alkyl or —O(C1-C6)alkyl; or R1 and R2 together represent —CH═CH—CH═CH—; R3 is (C1-C6)alkyl; X is —CH═CH— or —C≡C—; m is 1-10; n is 1-5; k is 1-3, with the proviso that when k is an integer of 2 or 3, n is independently 1-5 in each occurrence of the —X—(CH2)n— group; Y is —OR4, —CN, —C(=0)OR5, —C(=0)R5, or —C(=0)N(R6)2; R4 and R5 are independently selected from the group consisting of hydrogen, —(C1-C6)alkyl, —(C1-C6)haloalkyl, —C(=0)-(C1-C6)alkyl, —C(=0)-(C1-C6)haloalkyl, —C(=0)-NH(C1-C6)alkyl, —C(=0)-N((C1-C6)alkyl)2, —C(=0)-NH2, and phenyl, wherein the phenyl group may optionally be substituted with a substituent selected from the group consisting of —(C1-C6)alkyl, -0-(C1-C6)alkyl, —(C1-C6)haloalkyl, and halo; each R6 is independently hydrogen or —(C1-C6)alkyl; and M is —H, —C(0)—R7 or —C(0)0-R7, wherein R7 is —(C1-C6)alkyl or phenyl; or a stereoisomer, mixture of stereoisomers, pharmaceutically acceptable salt, crystalline form, non-crystalline form, hydrate or solvate thereof. | ||||||
| 22 | TREATMENT OF OSTEOPOROSIS | US13518621 | 2010-12-22 | US20130030050A1 | 2013-01-31 | Stephen Hodges; Robin Soper |
| According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia. | ||||||
| 23 | ELECTRODE ACTIVE MATERIAL FOR ELECTRICITY STORAGE DEVICE, AND ELECTRICITY STORAGE DEVICE USING SAME | US13583880 | 2011-03-11 | US20130004836A1 | 2013-01-03 | Yu Otsuka; Nobuhiko Hojo; Takafumi Tsukagoshi; Toshiki Nokami; Jun-Ichi Yoshida |
| The present invention provides an electrode active material for an electricity storage device, having a structure represented by following formula (1). In the formula (1), R1 to R6 each denote independently a hydrogen atom (except for a case where all of R1 to R6 denote hydrogen atoms), a halogen atom, an optionally substituted phenyl group, an optionally substituted heterocyclic group, or an optionally substituted hydrocarbon group having 1 to 4 carbon atoms. | ||||||
| 24 | Anthracyclinone derivatives | US946578 | 1997-10-07 | US5998615A | 1999-12-07 | Antonino Suarato; Jacqueline Lansen; Michele Caruso; Dario Ballinari; Tiziano Bandiera |
| The present invention provides the new use in the treatment of amyloidosis with the anthracyclinone of formula (A) wherein R1, R2, R3, R4, and R5, are appropriate substituents. Some compounds of formula (A) are novel. Processes for their preparation and pharmaceutical composition containing them are also described. | ||||||
| 25 | Use of anthracyclinone derivatives in amyloidosis | US615182 | 1996-04-04 | US5731313A | 1998-03-24 | Antonino Suarato; Jacqueline Lansen; Michele Caruso; Dario Ballinari; Tiziano Bandiera |
| The present invention provides the new use in the treatment of amyloidosis with the anthracyclinone of formula (A) wherein R1, R2, R3, R4, and R5, are appropriate substituents. Some compounds of formula (A) are novel. Processes for their preparation and pharmaceutical composition containing them are also described. | ||||||
| 26 | Substituted naphthacene-5,12-diones and their use | US843656 | 1992-02-28 | US5391749A | 1995-02-21 | Walter Fischer; Marcus Baumann; Jurgen Finter; Vratislav Kvita; Carl W. Mayer; Wolfgang Wernet |
| Substituted naphthacenediones of the formula I ##STR1## in which R.sup.1 to R.sup.8 are H and at least one of R.sup.1 to R.sup.8, for example R.sup.2 and R.sup.3 or R.sup.2 and R.sup.6, are, for example, C.sub.1 -C.sub.20 alkoxy, C.sub.1 -C.sub.20 alkenoxy, C.sub.1 -C.sub.20 -alkylsulfinyl, --CN, --CF.sub.3, --NO.sub.2, --Si(CH.sub.3).sub.3 or --COO(C.sub.1 -C.sub.12 alkyl), are suitable, when incorporated into polymers having hydroxyalkyl groups, for currentless deposition of metals onto the polymer surface. They are in some cases suitable as photoinitiators. | ||||||
| 27 | Carminomycinone precurses and analogues | US758560 | 1985-06-18 | US4822873A | 1989-04-18 | Donald W. Cameron; Geoffrey I. Feutrill; Peter G. Griffiths |
| A compound of formula II and tautomeric forms thereof wherein:R.sub.1 -R.sub.4 are H, alkyl, aryl, alkaryl, halogen, hydroxy, alkoxy, aryloxy, aralkoxy, acyloxy, amino or alkylamino:R.sub.8 has the same meaning as given to R.sub.1 -R.sub.4 or may be glycosyloxy;R.sub.9 and R.sub.12 have the same meaning as given to R.sub.1 -R.sub.4 and alternatively may be alkoxycarbonyl, aryloxycarbonyl or carboxy;one of R.sub.x or R.sub.b is hydroxy and the other is H, hal, alkoxy, aryloxy or acyloxy;R.sub.10 and R.sub.11 taken together are oxo or ethylenedioxy (provided that if R.sub.1 and R.sub.11 taken together are ethylenedioxy then if R.sub.4 is hydrogen or methoxy, R.sub.b is not hydrogen or acetoxy); orR.sub.10 is hydroxy; andR.sub.11 is hydroxyalkyl or dihydroxyalkyl or --CO--R.sub.15 whereR.sub.15 is H, alkyl, aryl, aralkyl, hydroxyalkyl. | ||||||
| 28 | Quinine derivatines | US165009 | 1980-07-01 | US4818441A | 1989-04-04 | Isuke Imada; Shinji Terao; Mitsuru Kawada; Mitsuru Shiraishi |
| A compound of the general formul: ##STR1## wherein .alpha. .beta. means a saturated bond or a double bond; each R independently of one another is a methyl group or a methoxy group, or two R's taken together represent a group of --CH.dbd.CH--CH.dbd.CH--; n is zero or an integer of 1 through 9; when .alpha. .beta. is a saturated bond, R.sub.2 is a hydrogen atom or hydroxyl group, and when .alpha. .beta. is a double bond, R.sub.2 is a hydrogen atom; when .alpha. .beta. is a double bond or when R.sub.2 is a hydroxyl group, R.sub.1 is a carboxyl group, a group of CH.sub.2.sub.2m OH (wherein m is an integer of 1 through 3) or a group of ##STR2## (wherein m is an integer of 1 through 3); when .alpha. .beta. is a saturated bond and R.sup.2 is a hydrogen atom, R.sub.1 is a hydroxymethyl group or a group of ##STR3## (wherein m is an integer of 1 through 3) has pharmacological actions such as membrane stabilizing activity (e.g. lysosomal membrane stabilizing activity), mitochondrial electron transport activity, hypotensive activity, activity to inhibit cardiac hypertrophy, tracheal muscle relaxant activity, cerebral circulation improving activity and cerebral ischemia preventive activity and is of value in the prophylaxis and treatment of hypertension, cardiac failure, asthma, cerebral apoplexy and other diseases, as a cardiac failure remedy, bronchodilator, cerebral circulation improving agent or the like. | ||||||
| 29 | Method and apparatus for keeping and supplementing goods | US097644 | 1987-09-16 | US4806072A | 1989-02-21 | Etsuo Karashima |
| A method for keeping goods and, if necessary, supplementing them to showcases in a shopping floor is disclosed. Also an apparatus to be used for practicing this method is disclosed. A group of temporary goods keeping carts each having multi-level shelves are disposed on standby at a temporary goods holding place in a store warehouse leading to a shopping floor, good receiving carts brought into the warehouse and the temporary goods keeping carts are moved to working tables within the warehouse, where the goods on the goods receiving carts are classified and accommodated in goods holding trays, thereafter the trays are placed on the respective shelves in the temporary goods keeping carts, then the temporary goods keeping carts are returned to the temporary goods holding place, subsequently goods supplementing carts each having shelves at a plurality of levels are brought to the temporary goods holding place, the trays on the respective shelves in the temporary goods keeping carts are transferred onto the respective shelves in the goods supplementing carts, then the goods supplementing carts are brought to the shopping floor, or the temporary goods keeping carts are directly brought to the shopping floor, and the goods in the trays on the respective shelves in the goods supplementing carts or in the temporary goods keeping carts are displayed in showcases in the shopping floor. | ||||||
| 30 | Benzoquinone derivatives and production thereof | US717098 | 1985-03-28 | US4751303A | 1988-06-14 | Shinji Terao; Hisayoshi Okazaki; Isuke Imada |
| A novel benzoquinone derivative of the general formula: ##STR1## [wherein R.sub.1 and R.sub.2 are the same or different and each is methyl or methoxy; n is an integer of 0 to 21; m is 0 or 1, Z is a group of the formula: (wherein R.sub.3 and R.sub.4 are the same or different and each is hydrogen or an alkyl group which may optionally be substituted or, R.sub.3 and R.sub.4 together with the adjacent nitrogen atom form a morpholino group), a group of the formula: --COR.sub.5 (wherein R.sub.5 is an .alpha.-amino acid residue or a substituted or unsubstituted glucosamine residue), a group of the formula: ##STR2## (wherein R.sub.6 is a divalent hydrocarbon group of 1 to 3 carbon atoms), a group of the formula: ##STR3## (wherein R.sub.6 has the same meaning as defined above) or a group of the formula: --CH.dbd.CH).sub.l COR.sub.7 (wherein l is an integer of 1 to 4 and R.sub.7 is hydroxy, methoxy or methyl)] has protocollagen-proline hydroxylase inhibiting activity, collagen biosynthesis inhibiting activity and 5-lipoxygenase suppressant activity, and is useful for the prevention and treatment of such diseases as pulmonary fibrosis, hepatocirrhosis, nephrosclerosis, arteriosclerosis, scleroderma, myelofibrosis and chronic arthritis or for the prevention and treatment of asthma, allergic rhinitis, urticaria, etc. | ||||||
| 31 | Hydroquinone ether compounds | US743473 | 1985-06-07 | US4616082A | 1986-10-07 | Frederick H. Howell |
| New hydroquinone ether compounds of formula I are described: ##STR1## wherein p is 1 or 2 and Q is 0 or 1, provided that p+q is 1 or 2, R is a residue of formula II ##STR2## and R.sub.o, R.sub.oo, R.sub.1, R.sub.2, R.sub.3, Q, n and k are as defined in the specification,The new compounds are useful e.g. as stabilizers in photographic material. | ||||||
| 32 | Aralkyl carboxylic acid compounds in compositions for potentiating immuno activity | US497014 | 1983-05-23 | US4525361A | 1985-06-25 | Hiroshi Morimoto; Isuke Imada; Masazumi Watanabe; Mitsuru Kawada |
| Novel compounds of the formulae ##STR1## wherein R represents lower alkyl or lower alkoxy, A represents --CH.sub.2 --, --CO-- or ##STR2## n represents an integer of 1 to 8, X represents hydrogen or hydroxyl which may be protected and Y represents hydroxyl which may be protected, and their esters show an excellent action on the lysosomal membranes of cells, and exhibit excellent pharmacological activities such as physiologic host defense control activity, especially immuno-potentiating activity. | ||||||
| 33 | Antifibrotic agent | US479074 | 1983-03-25 | US4514420A | 1985-04-30 | Isuke Imada; Masazumi Watanabe |
| Compounds of the formula ##STR1## wherein A is methylene or carbonyl, n is an integer of 2 to 21, inclusive, and R is hydrogen or lower alkyl, are effective for the prophylaxis or treatment of mammals suffering from fibrosis due to excessive collagen accumulation. | ||||||
| 34 | Quinone carboxylic acids and ester derivatives | US167522 | 1980-07-11 | US4495104A | 1985-01-22 | Isuke Imada; Tetsuya Okutani; Masazumi Watanabe |
| A compound of the general formula ##STR1## wherein n is an integer of 10 to 21, inclusive; R is H or lower alkyl having 1 to 4 carbon atoms has pharmaceutical activities such as hypotensive, tissue metabolism stimulating, immuno-regulatory, lysosomal membrane stabilizing and SRS-A production inhibitory activities and is useful as a heart failure remedy, cerebral circulation disturbance remedy, immuno-regulator, and antiallergic drug. | ||||||
| 35 | Quinone compounds, their production and use | US511083 | 1983-07-05 | US4489096A | 1984-12-18 | Shinji Terao; Yoshitaka Maki |
| New quinone compounds of the formula: ##STR1## wherein R is methyl or methoxy andY is formyl, carboxyl, an alkoxycarbonyl having 2 to 5 carbon atoms, carbamoyl, a mono- or di- alkylcarbamoyl whose alkyl moiety has 1 to 4 carbon atoms or carbamoyloxymethyl, ortheir hydroquinone-form compounds, or pharmaceutically acceptable salts thereof, have useful physiological activities such as antiasthmatic and antiallergic activities. | ||||||
| 36 | 6-Hydroxy-1,4-benzoquinone compounds | US961021 | 1978-11-15 | US4271083A | 1981-06-02 | Hiroshi Morimoto; Isuke Imada; Masazumi Watanabe; Mitsuru Kawada |
| Novel compounds of the formula ##STR1## wherein R represents lower alkyl or lower alkoxy, A represents --CH.sub.2 --, --CO-- or ##STR2## n represents an integer of 1 to 8, X represents hydrogen or hydroxyl which may be protected and Y represents hydroxyl which may be protected, and their esters show an excellent action on the lysosomal membranes of cells, and exhibit excellent pharmacological activities such as physiologic host defense control activity, especially immuno-potentiating activity. | ||||||
| 37 | Anthracycline synthesis | US908256 | 1978-05-22 | US4215062A | 1980-07-29 | Lester A. Mitscher |
| A process for synthesizing doxorubicin and related compounds from aloe-emodin is disclosed. Intermediates useful in the preparation of doxorubicin and related compounds are also disclosed. | ||||||
| 38 | Photographic products and processes employing novel nondiffusible heterocyclylazonaphthol dye-releasing compounds | US002127 | 1979-01-09 | US4207104A | 1980-06-10 | Derek D. Chapman; E-Ming Wu |
| Photographic elements, diffusion transfer assemblages and processes are described which employ a novel nondiffusible compound having a releasable 2-(2-heterocyclylazo)-1-naphthol dye moiety which contains a nitrogen atom adjacent to the point of attachment to the azo linkage. The compound contains a ballasted carrier moiety which is capable of releasing the diffusible azo dye under alkaline conditions. The dye is transferred imagewise to an image-receiving layer where it is contacted with metal ions to form a metal-complexed azo dye transfer image of excellent stability. | ||||||
| 39 | Introduction of organic radicals into quinones | US50028843 | 1943-08-27 | US2398418A | 1946-04-16 | FIESER LOUIS F |
| 40 | CANNABIGEROL QUINONE ACID AND SALTS THEREOF | US17413199 | 2019-12-11 | US20220041538A1 | 2022-02-10 | Eduardo MUÑOZ BLANCO; Giovanni APPENDINO |
| A compound of formula I or a pharmaceutical salt thereof of formula II, as well as a process to obtain said compound and a process to obtain said salt. Additionally, disclosed is the use of said compound of formula I or said pharmaceutical salt thereof of formula II as a medicament, in particular as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, for use in the treatment or prevention of a disease responsive to PPARγ agonists. Also disclosed is a pharmaceutical composition comprising said compound or said salt, as well as a method of treating or preventing a disease with said compound of formula I or said salt thereof of formula II, or with a composition comprising said compound or said salt. | ||||||
QQ群二维码
意见反馈
意见反馈